Mainz Biomed N.V. announced a License and Option Agreement with Liquid Biosciences, gaining access to a portfolio of novel mRNA biomarkers for the non-invasive detection of pancreatic cancer via a blood test. This marks a significant expansion of the company's PancAlert program.
Discovery analysis, conducted across multiple independent pancreatic cancer study cohorts, demonstrated exceptional accuracy. The biomarkers, combined with a proprietary algorithm, achieved an overall sensitivity of 95% and a specificity of 98% for detecting pancreatic cancer in blood samples.
Mainz Biomed has secured exclusive rights to license this biomarker portfolio, with a unilateral option to acquire exclusive global rights. The parties plan to jointly develop this screening test, including commercial assay enhancement and algorithm refinement, in preparation for potential FDA application and approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.